Your browser is no longer supported. Please, upgrade your browser.
Aravive, Inc.
Index- P/E- EPS (ttm)-2.05 Insider Own1.20% Shs Outstand16.06M Perf Week-6.45%
Market Cap86.18M Forward P/E- EPS next Y-2.06 Insider Trans9.32% Shs Float11.23M Perf Month-10.84%
Income-30.80M PEG- EPS next Q-0.52 Inst Own41.00% Short Float5.81% Perf Quarter11.76%
Sales0.00M P/S- EPS this Y85.20% Inst Trans-0.14% Short Ratio4.27 Perf Half Y-17.27%
Book/sh3.07 P/B1.79 EPS next Y7.20% ROA-43.10% Target Price- Perf Year-48.41%
Cash/sh3.45 P/C1.60 EPS next 5Y- ROE-52.10% 52W Range3.34 - 14.94 Perf YTD-2.30%
Dividend- P/FCF- EPS past 5Y43.10% ROI- 52W High-63.12% Beta3.24
Dividend %- Quick Ratio11.40 Sales past 5Y- Gross Margin- 52W Low64.97% ATR0.36
Employees17 Current Ratio11.40 Sales Q/Q- Oper. Margin- RSI (14)43.93 Volatility6.20% 6.48%
OptionableYes Debt/Eq0.00 EPS Q/Q-22.00% Profit Margin- Rel Volume0.92 Prev Close5.90
ShortableYes LT Debt/Eq0.00 EarningsNov 05 AMC Payout- Avg Volume152.91K Price5.51
Recom1.70 SMA20-3.60% SMA50-6.08% SMA200-31.23% Volume141,505 Change-6.61%
Sep-18-20Initiated William Blair Outperform
Dec-10-19Initiated Cantor Fitzgerald Overweight
Dec-02-19Upgrade Robert W. Baird Neutral → Outperform
May-13-19Initiated Piper Jaffray Overweight $10
Apr-09-19Initiated Wedbush Outperform $14
Jan-04-21 04:05PM  
Dec-31-20 07:00PM  
Dec-07-20 09:37PM  
Nov-19-20 07:00AM  
Nov-16-20 11:19PM  
Nov-10-20 04:05PM  
Nov-05-20 04:05PM  
Sep-17-20 07:00AM  
Sep-15-20 07:00AM  
Sep-08-20 07:00AM  
Aug-27-20 07:00AM  
Aug-13-20 03:30PM  
Aug-03-20 04:01PM  
Jul-30-20 07:00AM  
Jul-23-20 07:00AM  
Jul-03-20 01:11PM  
Jul-01-20 08:12AM  
Jun-30-20 04:05PM  
Jun-24-20 05:45PM  
Jun-17-20 05:50PM  
Jun-12-20 12:04PM  
May-12-20 08:00AM  
May-06-20 04:05PM  
May-05-20 05:45PM  
Apr-30-20 08:00AM  
Apr-27-20 05:45PM  
Apr-22-20 07:10AM  
Apr-20-20 09:06AM  
Apr-16-20 10:40AM  
Apr-15-20 08:45AM  
Apr-09-20 07:08AM  
Mar-30-20 08:00AM  
Mar-27-20 08:00AM  
Mar-24-20 08:00AM  
Feb-25-20 04:07PM  
Feb-18-20 08:00AM  
Jan-13-20 08:00AM  
Jan-10-20 07:13AM  
Jan-09-20 04:05PM  
Jan-02-20 08:34AM  
Dec-23-19 07:57PM  
Dec-20-19 08:00AM  
Dec-02-19 08:00AM  
Nov-29-19 08:51AM  
Nov-27-19 08:30AM  
Nov-26-19 05:14PM  
Nov-20-19 04:26PM  
Nov-12-19 08:00AM  
Nov-08-19 01:11PM  
Nov-07-19 04:05PM  
Nov-03-19 07:41AM  
Oct-18-19 08:00AM  
Sep-27-19 10:15AM  
Sep-19-19 08:13AM  
Sep-18-19 08:00AM  
Aug-08-19 04:15PM  
Aug-07-19 08:55PM  
Jul-31-19 03:16PM  
Jul-08-19 07:05AM  
May-08-19 06:35PM  
Apr-25-19 02:26PM  
Mar-19-19 07:05AM  
Mar-15-19 07:48AM  
Mar-11-19 02:14PM  
Mar-08-19 04:05PM  
Mar-07-19 04:04PM  
Mar-05-19 04:05PM  
Feb-28-19 04:10PM  
Feb-19-19 07:00AM  
Feb-14-19 07:00AM  
Jan-29-19 07:00AM  
Dec-11-18 08:05AM  
Nov-26-18 07:00AM  
Nov-13-18 07:00AM  
Nov-06-18 06:38PM  
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, triple negative breast cancer, acute myeloid leukemia, and pancreatic cancer. The company has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shah VinayChief Financial OfficerDec 04Buy5.768,00046,080189,842Dec 07 08:05 PM
McIntyre Gail FrancesCEO and PresidentDec 04Buy5.778,00046,16010,137Dec 07 08:00 PM